October 2021
Katia Martínez-González, Leonor Serrano-Cuevas, Eduardo Almeida-Gutiérrez, Salvador Flores-Chavez, Juan Manuel Mejía-Aranguré, Paola Garcia-delaTorre
Abstract
Objectives: Alzheimer's disease (AD) correlates with the dysfunction of metabolic pathways that translates into neurological symptoms. An arginine deficiency, a precursor of nitric oxide (NO), has been reported for patients with AD. We aimed to evaluate the effect of citrulline oral supplementation on cognitive decline in an AD murine model.
Methods: Three-month citrulline or water supplementation was blindly given to male and female wild-type and 3 × Tg mice with AD trained and tested in the Morris water maze. Cerebrospinal fluid and brain tissue were collected. Ultra-performance liquid chromatography was used for arginine determinations and the Griess method for NO.
Results: Eight-month-old male 3 × Tg mice with AD supplemented with citrulline performed significantly better in the Morris water maze task. Arginine levels increased in the cerebrospinal fluid although no changes were seen in brain tissue and only a tendency of increase of NO was observed.
Conclusions: Citrulline oral administration is a viable treatment for memory improvement in the early stages of AD, pointing to NO as a viable, efficient target for memory dysfunction in AD.
Keywords: Arginine; Dementia; Hippocampus; Nitric oxide; Nutritional supplementation.
Copyright © 2021 Elsevier Inc. All rights reserved.
